Hormonal
SGLT2 inhibitors reduce major adverse cardiovascular events (MACE) by 11% and heart failure hospitalization by 23% in patients with type 2 diabetes and established cardiovascular disease.
If you have Type 2 Diabetes and heart disease or heart failure, ask your doctor about SGLT2 inhibitors (like empagliflozin or dapagliflozin). These drugs not only help control blood sugar but have been proven to significantly reduce the risk of heart attacks, strokes, and hospitalizations for heart failure, regardless of your current blood sugar levels.
A meta-analysis of three studies showed that sodium-glucose cotransporter 2 (SGLT2) inhibitors reduced major adverse CV events by 11% in patients with T2DM and atherosclerotic CVD and reduced the risk of CV death or hospitalization for HF by 23%...
Why this rating
Based on a meta-analysis of three studies and multiple large CVOTs.
Source
Cardiovascular disease in type 2 diabetes mellitus: progress toward personalized management
Chengxu Ma et al. · Cardiovascular Diabetology · 2022
DOI 10.1186/s12933-022-01516-6
More from this paper
- GLP-1 receptor agonists reduce major adverse cardiovascular events (MACE) by 14% and all-cause mortality by 12% in patients with type 2 diabetes.Good
- Metformin reduces all-cause mortality by 36% and heart attack incidence by 39% in overweight patients with newly diagnosed type 2 diabetes without established cardiovascular disease.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →